Danaher Corporation $DHR Shares Sold by Savant Capital LLC

Savant Capital LLC cut its position in shares of Danaher Corporation (NYSE:DHR) by 16.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 42,757 shares of the conglomerate’s stock after selling 8,275 shares during the quarter. Savant Capital LLC’s holdings in Danaher were worth $9,788,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Elevated Capital Advisors LLC acquired a new position in shares of Danaher in the fourth quarter worth $26,000. JPL Wealth Management LLC acquired a new position in shares of Danaher in the third quarter worth $25,000. WFA of San Diego LLC acquired a new position in shares of Danaher in the second quarter worth $26,000. ANTIPODES PARTNERS Ltd acquired a new position in shares of Danaher in the third quarter worth $27,000. Finally, MidAtlantic Capital Management Inc. acquired a new position in shares of Danaher in the fourth quarter worth $33,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Price Performance

Shares of NYSE:DHR opened at $182.73 on Friday. The company has a market cap of $129.33 billion, a P/E ratio of 35.34, a P/E/G ratio of 2.41 and a beta of 0.81. The company has a quick ratio of 1.52, a current ratio of 1.87 and a debt-to-equity ratio of 0.33. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The business has a fifty day simple moving average of $182.11 and a 200-day simple moving average of $207.48.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, April 20th. The conglomerate reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. The business had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $6 billion. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The business’s revenue for the quarter was up 3.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.88 earnings per share. Equities research analysts forecast that Danaher Corporation will post 8.43 EPS for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be given a $0.40 dividend. The ex-dividend date of this dividend is Friday, June 26th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.9%. Danaher’s payout ratio is currently 30.95%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on DHR. Royal Bank Of Canada began coverage on Danaher in a report on Thursday, May 14th. They issued an “outperform” rating and a $200.00 price target for the company. Argus cut their price target on Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a report on Friday, April 24th. Guggenheim cut their price target on Danaher from $275.00 to $235.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Barclays cut their price target on Danaher from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. Finally, Wolfe Research cut their price target on Danaher from $260.00 to $230.00 and set an “outperform” rating for the company in a report on Wednesday, April 8th. Twenty research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $238.24.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.